Dosage Questions FAQ

Important: This page is educational information only. Psilocybin is a controlled substance in most jurisdictions. Do not use these dosage figures as personal dosing guidance. Consult a medical professional if you have health conditions, take medications, or have a psychiatric history before considering any psychedelic substance.

How Much Psilocybin Is in a Dried Mushroom?

Psilocybin content in dried mushrooms varies considerably between species, between individual specimens, and even between different flushes of the same cultivated batch. The most widely cultivated species, Psilocybe cubensis, averages approximately 0.63% psilocybin by dry weight in most cultivated varieties — meaning 1 gram of dried mushroom contains roughly 6–7 mg of psilocybin. However, potency can range from around 0.2% to over 1.5% depending on the specific strain and growing conditions. Potency testing with reagent kits or laboratory analysis is the only way to verify content.

The conversion factor from fresh to dried mushrooms is approximately 10:1 — 10 grams of fresh mushrooms yield approximately 1 gram dried. Fresh mushrooms contain roughly 90% water, so their psilocybin content by weight is approximately one-tenth that of dried material.

Standard Dose Categories for Dried Psilocybe cubensis

The following ranges represent approximate guidelines based on research literature and harm-reduction community consensus for dried P. cubensis specifically. These figures cannot be directly applied to other species, particularly high-potency varieties.

What Is a Microdose?

A microdose is a dose below the threshold of perceptual alteration — typically 0.05–0.3 g of dried P. cubensis, or approximately 1–3 mg of psilocybin. At a true microdose, there should be no visual changes, no impairment of coordination or cognition, and no sense of being "on" a substance. The goal is to remain fully functional while potentially experiencing subtle improvements in mood, focus, creative thinking, or emotional regulation.

Microdosing protocols vary. The most commonly referenced (popularised by researcher James Fadiman) involves dosing every third day — one day on, two days off — to prevent tolerance accumulation. The Stamets Protocol uses four days on, three days off, often with additional supplements including lion's mane mushroom and niacin.

The evidence base for microdosing remains limited. Most studies to date are observational (based on self-report), small, or have methodological limitations. Controlled clinical trials are underway but results are not yet definitive. Many of the reported benefits may be attributable to expectation effects. This does not mean microdosing does not work — it means the evidence base does not yet support confident claims about efficacy.

Why Do Species and Strain Matter?

Different species of psilocybin mushrooms vary significantly in potency. Psilocybe cubensis is the most widely cultivated and has a relatively well-characterised potency range. Other species are considerably stronger:

• Psilocybe azurescens — estimated 1.0–1.8% psilocybin; roughly 2–3x the potency of average P. cubensis
• Psilocybe semilanceata (Liberty Cap) — 0.2–2.0% psilocybin, with wide variation; potent and difficult to dose reliably
• Psilocybe cyanescens — 0.5–1.9% psilocybin; stronger than P. cubensis

This is why dose ranges derived from P. cubensis experience cannot be safely applied to other species. If you are working with a species other than P. cubensis, reduce your expected dose significantly until you understand the potency.

How Does Tolerance Work?

Psilocybin produces rapid and near-complete cross-tolerance with LSD and mescaline. After a full-dose psilocybin experience, repeating the same dose 24–48 hours later will produce dramatically reduced effects. Tolerance typically returns to baseline within 2 weeks. This is why the 2-week minimum gap between full-dose sessions is a consistent harm-reduction recommendation. Attempting to overcome tolerance by taking substantially higher doses is neither effective nor safe.

The rapid tolerance development also explains why psilocybin is considered to have low addiction potential — unlike substances where tolerance drives escalating use, psilocybin's rapid tolerance effectively prevents frequent re-dosing from producing desired effects.

What Affects How Strong the Effects Feel?

Even with a fixed dose of known psilocybin content, the experienced intensity varies significantly based on:

• Fasting status: Taking psilocybin on an empty stomach (3–4 hours fasted) typically produces faster onset and more intense effects than taking it after a meal
• Preparation method: Lemon tek (steeping in acidic lemon juice) pre-converts psilocybin to psilocin and may produce faster, more intense onset, often with shorter duration
• Individual metabolism: Body weight, liver enzyme variation (particularly CYP2D6), and individual neurological sensitivity all affect response; these cannot be predicted reliably
• Mental and emotional state (set): Anxiety, emotional resistance, and unresolved psychological material can intensify challenging aspects of the experience regardless of dose
• Medications: SSRIs and SNRIs significantly blunt psilocybin effects; lithium increases seizure risk; MAOIs dramatically intensify effects and can be dangerous

Can You Take Too Much? What Happens?

Psilocybin has an extremely high physiological safety margin — there are no confirmed human deaths from psilocybin toxicity alone, and the lethal dose in animal studies requires quantities far beyond what any human could consume. However, "too much" in a psychological sense is entirely possible and common: experiences that become overwhelming, panic-inducing, terrifying, or that involve profound disorientation and loss of reality testing are regularly reported, particularly at high doses without adequate preparation or support.

The harm from high-dose psilocybin experiences is psychological, behavioural (injury from confused or panicked behaviour), and — rarely — psychiatric (persisting perception disorders or exacerbation of pre-existing conditions). This is why set, setting, appropriate dosing, and the presence of a sober, experienced support person are not optional recommendations but core components of responsible use.

Conclusion

Dosage is the single variable most within a user's control for determining the nature and intensity of a psilocybin experience. Starting lower than you think you need — particularly on your first or second experience — is the most consistent harm-reduction recommendation across research, clinical, and community sources. The principle is simple: you can always have a deeper experience next time; you cannot undo an overwhelming experience once it has begun.